{
  "data": {
    "id": "stat_9E0RAKBAYRXN38BF6BZ10XQBDS",
    "url": "https://statorigin.org/stat/stat_9E0RAKBAYRXN38BF6BZ10XQBDS",
    "indicator": {
      "slug": "ctgov-kras-registered-trials",
      "name": "Registered interventional KRAS and RAS inhibitor trials",
      "definition": "Count of interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) on ClinicalTrials.gov, any start date."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "GLOBAL",
      "name": "Global",
      "type": "world"
    },
    "period": {
      "start": "2026-09-27",
      "end": "2026-09-27",
      "type": "point"
    },
    "value": 322,
    "value_text": "322 studies",
    "unit": "count",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
      "org_short_name": "ClinicalTrials.gov",
      "org_url": "https://clinicaltrials.gov",
      "org_tier": 1,
      "document_title": "ClinicalTrials.gov study count: All interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents), any start date, as registered on 2026-09-27",
      "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId",
      "document_type": "dataset",
      "locator": "totalCount field of the API response. Query: All interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents), any start date, as registered on 2026-09-27.",
      "quote": "{\"totalCount\":322,\"studies\":[",
      "published_date": null,
      "accessed_at": "2026-09-27",
      "license": "public-domain",
      "url_status": "ok",
      "self_reported": false
    },
    "verification": "verified",
    "verified_by": "pipeline:ctgov-api-totalcount-verified",
    "verified_at": "2026-09-27T12:00:00.000Z",
    "confidence": 0.95,
    "is_secondhand": false,
    "supersedes": "stat_ZG75ZQVMERP7B21K6VZGD7HK0N",
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: All interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents), any start date, as registered on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_9E0RAKBAYRXN38BF6BZ10XQBDS",
      "bibtex": "@misc{clinicaltrialsgo2026ctgov0xqbds,\n  author       = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n  title        = {ClinicalTrials.gov study count: All interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents), any start date, as registered on 2026-09-27},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_9E0RAKBAYRXN38BF6BZ10XQBDS},\n  note         = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib\\%20OR\\%20adagrasib\\%20OR\\%20divarasib\\%20OR\\%20daraxonrasib\\%20OR\\%20RMC-6236\\%20OR\\%20elironrasib\\%20OR\\%20RMC-6291\\%20OR\\%20zoldonrasib\\%20OR\\%20RMC-9805\\%20OR\\%20olomorasib\\%20OR\\%20garsorasib\\%20OR\\%20fulzerasib\\%20OR\\%20glecirasib\\%20OR\\%20MRTX1133\\%20OR\\%20\\%22KRAS\\%20G12C\\%20inhibitor\\%22\\%20OR\\%20\\%22KRAS\\%20G12D\\%20inhibitor\\%22\\%20OR\\%20\\%22pan-KRAS\\%22\\%20OR\\%20\\%22pan-RAS\\%22\\%20OR\\%20\\%22KRAS\\%20inhibitor\\%22\\%20OR\\%20opnurasib\\%20OR\\%20D-1553\\%20OR\\%20LY3537982\\%20OR\\%20HRS-4642\\%20OR\\%20INCB161734\\%20OR\\%20ASP3082\\%20OR\\%20setidegrasib\\%20OR\\%20\\%22AMG\\%20510\\%22\\%20OR\\%20MRTX849\\%20OR\\%20GDC-6036\\%20OR\\%20G12D\\%20OR\\%20GFH925\\%20OR\\%20IBI351\\%20OR\\%20JAB-21822\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}"
    },
    "updated_at": "2026-09-27T01:11:36.992Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}